High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG)

@article{Weide2007HighAA,
  title={High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG)},
  author={Rudolf Weide and Georg Hess and Hubert K{\"o}ppler and Jochen Heymanns and J{\"o}rg Thomalla and Ali Aldaoud and Christoph Losem and Stefan Schmitz and Ursula Haak and Christoph Huber and Michael Unterhalt and Wolfgang Hiddemann and Martin Dreyling},
  journal={Leukemia \& Lymphoma},
  year={2007},
  volume={48},
  pages={1299 - 1306}
}
On the basis of a preceding phase I study, the current trial explored bendamustine in combination with mitoxantrone and rituximab (BMR) in patients with stage III/IV relapsed or refractory indolent lymphomas and mantle cell lymphoma (MCL) with or without prior rituximab containing chemo-immunotherapy (R-chemo) treatment. Therapy consisted of bendamustine 90 mg/m2 days 1 + 2, mitoxantrone 10 mg/m2 day 1, rituximab 375 mg/m2 day 8. Treatment was repeated on day 29 for a total of four cycles… 
Final Results of a Phase I/II Trial of the Combination Bendamustine and Rituximab With Temsirolimus (BeRT) in Relapsed Mantle Cell Lymphoma and Follicular Lymphoma
TLDR
Data demonstrates promising efficacy of Temsirolimus in r/r MCL and FL with acceptable toxicity and the BeRT regimen may be used as a treatment option for both entities.
A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma – long-term results of a multicenter observation study
TLDR
The combination of bortezomib and a high-dose cytarabine-containing regimen has activity in heavily pretreated patients with relapsed or refractory MCL.
A brief rituximab, bendamustine, mitoxantrone (R‐BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL)
TLDR
A brief R‐BM regimen plus rituximab consolidation is effective and safe in “FIT” elderly, treatment‐naïve, FL patients, inducing high CR and molecular remission rates with prolonged PFS.
Retreatment with bendamustine-containing regimens in patients with relapsed/refractory chronic lymphocytic leukemia and indolent B-cell lymphomas achieves high response rates and some long lasting remissions
TLDR
Bendamustine retreatment is feasible and achieves high response rates and some long lasting remissions in outpatients with CLL and NHL.
Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem‐cell transplantation or conventional chemotherapy: results of a Phase I clinical trial
TLDR
BPT therapy was well tolerated in patients with relapsed or refractory MM, with a response rate higher than 80%.
Bortezomib in mantle cell lymphoma.
TLDR
Front-line therapy appears to benefit from intensification either through high-dose therapy with stem cell transplant consolidation or dose-intense chemotherapy with hyperfractionated cyclophosphamide, vincristine, adriamycin/doxorubicin and dexamethasone/rituximab.
Bendamustine-containing immunochemotherapy is active in transformed follicular lymphoma with overexpression of p53
TLDR
Bendamustine as single-agent produced a high rate of responses with acceptable toxicity in this heavily pretreated group of patients and achieved responses even in patients with transformed disease, although time to progression was relatively short.
Bendamustine: a review of its use in the management of indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
TLDR
Bendamustine is a unique alkylating agent, which in clinical trials has demonstrated consistent efficacy and acceptable tolerability in patients with indolent NHL or MCL.
Bendamustine in lymphomas: More to combine?
TLDR
The results of a multicenter phase II trial of bendamustine in combination with mitoxantrone and rituximab (BMR regimen) in 57 patients with pretreated indolent lymphomas or MCL show clinical efficacy in tumors refractory to conventional alkylating agents.
Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma
TLDR
Responses to repeated immunotherapy with rituximab were observed in approximately one third and two thirds of initially responding patients with aggressive B cell lymphoma and mantle cell lymphomas, respectively, but not in primarily refractory disease.
...
...

References

SHOWING 1-10 OF 19 REFERENCES
Bendamustine/Mitoxantrone/Rituximab (BMR): A Very Effective, Well Tolerated Outpatient Chemoimmunotherapy for Relapsed and Refractory CD20-positive Indolent Malignancies. Final Results of a Pilot Study
TLDR
BMR is a well tolerated very effective outpatient treatment for relapsed and refractory CD20-positive indolent lymphomas and CLL and the time to next antilymphoma treatment is prolonged significantly by BMR.
Bendamustine Mitoxantrone and Rituximab (BMR): A New Effective Regimen for Refractory or Relapsed Indolent Lymphomas
TLDR
In conclusion, BMR is a well tolerated, very effective outpatient regimen of treatment for relapsed and refractory indolent lymphoid malignancies.
Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma.
  • M. Rummel, S. Al-Batran, P. Mitrou
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005
TLDR
These results demonstrate that the BR combination is a highly active regimen in the treatment of low-grade lymphomas and mantle cell lymphomas.
Bendamustine HCl (TREANDATM) Treatment Results in High Rates of Objective Response in Patients with Rituximab-Refractory and Alkylator-Refractory Indolent B-Cell Non-Hodgkin’s Lymphoma (NHL): Results from a Phase II Multicenter Single-Agent Study (SDX-105-01).
TLDR
Single-agent bendamustine produced durable objective responses with acceptable toxicity, despite unfavorable prognostic features, in heavily pretreated rituximab-refractory indolent and transformed NHL patients.
Results of a Prospective Randomised Open Label Phase III Study Comparing Rituximab Plus Mitoxantrone, Chlorambucile, Prednisolone Chemotherapy (R-MCP) Versus MCP Alone in Untreated Advanced Indolent Non-Hodgkin’s Lymphoma (NHL) and Mantle-Cell-Lymphoma (MCL).
TLDR
Both regimens were well tolerated with a low incidence of serious adverse events and the overall response rate and the complete response rate for all pts was 85,5% and 42% in the R-MCP arm versus 65,5%" and 20%, in the MCP arm.
Bendamustine HCl (TREANDATM) Treatment in Combination with Rituximab Results in Objective Responses in Patients with Refractory/Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin’s Lymphoma: Results from Phase II Multicenter Study (SDX-105-02).
TLDR
Bendamustine, administered in combination with rituximab, produced high objective response rates with minimal toxicity in patients with refractory indolent and mantle cell NHL, including patients that previously failed alkylating and fludarabine-containing regimens.
High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas
  • K. Bremer
  • Medicine
    Journal of Cancer Research and Clinical Oncology
  • 2002
TLDR
Bendamustine proved to be very effective in pre-treated low-grade NHL patients by inducing high rates of long-lasting remissions and showed no cross-resistance to chlorambucil, melphalan, cyclophosphamide, mitoxantrone, and other anthracyclines.
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.
  • B. Cheson, S. Horning, G. Canellos
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1999
TLDR
Standardized guidelines for response assessment are needed to ensure comparability among clinical trials in non-Hodgkin's lymphomas (NHL), and two meetings were convened among United States and international lymphoma experts to develop a uniform set of criteria for assessing response in clinical trials.
CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma.
TLDR
The addition of rituximab to the CVP regimen significantly improves the clinical outcome in patients with previously untreated advanced follicular lymphoma, without increased toxicity.
...
...